Sutro Biopharma, Inc.
General ticker "STRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $237.9M (TTM average)
Sutro Biopharma, Inc. does not follow the US Stock Market performance with the rate: -2.0%.
Estimated limits based on current volatility of 17.3%: low 0.79$, high 1.12$
Factors to consider:
- Current price 24.3% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.19$, 3.72$]
- 2025-12-31 to 2026-12-31 estimated range: [1.29$, 3.76$]
Financial Metrics affecting the STRO estimates:
- Negative: Non-GAAP EPS, $ of -3.02 <= 0.04
- Negative: Operating cash flow per share per price, % of -51.49 <= 1.79
- Negative: negative Operating income
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
- Negative: Shareholder equity ratio, % of 11.52 <= 22.52
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share, $ of 0.40 <= 0.67
Short-term STRO quotes
Long-term STRO plot with estimates
Financial data
YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
---|---|---|---|
Operating Revenue | $67.77MM | $153.73MM | $62.04MM |
Operating Expenses | $196.72MM | $243.01MM | $300.50MM |
Operating Income | $-128.94MM | $-89.28MM | $-238.45MM |
Non-Operating Income | $12.24MM | $0.68MM | $13.36MM |
Interest Expense | $0.00MM | $12.57MM | $31.07MM |
R&D Expense | $137.17MM | $180.43MM | $252.04MM |
Income(Loss) | $-116.70MM | $-88.60MM | $-225.10MM |
Taxes | $2.50MM | $18.19MM | $2.36MM |
Profit(Loss)* | $-119.20MM | $-106.79MM | $-227.46MM |
Stockholders Equity | $217.05MM | $149.65MM | $44.60MM |
Inventory | $11.67MM | $0.00MM | $0.00MM |
Assets | $406.94MM | $470.74MM | $387.21MM |
Operating Cash Flow | $3.55MM | $-111.62MM | $-191.54MM |
Capital expenditure | $7.86MM | $4.32MM | $3.10MM |
Investing Cash Flow | $-35.02MM | $-3.92MM | $218.51MM |
Financing Cash Flow | $48.31MM | $137.55MM | $94.05MM |
Earnings Per Share** | $-2.35 | $-1.78 | $-2.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.